By vgreene, 11 June, 2019 NTRK (nuerotrophic receptor tyrosine kinase) gene testing: to identify metastatic CRC pts who may be candidates for larotrectinib1,2
By vgreene, 11 June, 2019 DNA Mismatch Repair (MMR)/Microsatellite Instability (MSI) testing: of tumor status (if not previously done)1,2 to identify CRC pts at high risk for Lynch syndrome and/or prognostic stratification;3 universal MMR or MSI testing recommended in all pts w/ p
By vgreene, 11 June, 2019 BRAF V600E mutational analysis:1-3 for all metastatic CRC pts, of the primary colorectal CAs and/or the metastasis to determine tumor gene status (along w/ KRAS, NRAS mutation testing);1,2 perform testing only in CLIA-certified "high-complexity" labs and
By vgreene, 11 June, 2019 DNA Mismatch Repair (MMR)/Microsatellite Instability (MSI) testing: of tumor status (if not previously done)1 to identify CRC pts at high risk for Lynch syndrome and/or prognostic stratification;3 universal MMR or MSI testing recommended in all pts w/ per
By vgreene, 10 June, 2019 HER2:1,2 Test tumor tissue of pts w/ advanced GEA who are potential candidates for HER2-targeted tx;3 request HER2 testing on tumor tissue or or resection specimens (primary or metastasis) preferably before initiating traastuzumab tx; acceptable alternati